Beyond the pill: new medication delivery options for ADHD
Andrew J Cutler1, Gregory W Mattingly2
11Chief Medical Officer,Florida Clinical Research Center,Bradenton,Florida.
CNS Spectrums
|July 8, 2017
Summary
Developing alternative medication formulations for pediatric attention-deficit/hyperactivity disorder (ADHD) is crucial. New dosage forms can improve adherence and treatment outcomes for children with ADHD.
Area of Science:
- Pediatric pharmacology
- Formulation science
Background:
- Pediatric disorders often require alternative medication formulations beyond tablets or capsules.
- Attention-deficit/hyperactivity disorder (ADHD) is a common chronic pediatric condition with complex co-occurring disorders.
- Existing ADHD treatments face challenges with adherence, swallowing difficulties, and dosing titration.
Purpose of the Study:
- To review strategies for developing alternative dosage forms in other disease areas.
- To discuss the application of these strategies for improving ADHD treatment.
- To explore how alternative formulations can address limitations in current ADHD medications.
Main Methods:
- Review of formulation development strategies in various disease areas.
- Analysis of challenges specific to pediatric ADHD medication.
- Discussion of the potential of alternative dosage forms for ADHD.
Main Results:
- Alternative formulations have successfully addressed challenges in other pediatric conditions.
- Strategies from other fields offer potential solutions for ADHD medication development.
- Once-daily long-acting formulations present a specific challenge for ADHD treatment.
Conclusions:
- Alternative dosage forms can enhance medication adherence, compliance, and patient preference in ADHD treatment.
- The development of novel formulations is essential for improving the overall management of pediatric ADHD.
- Applying strategies from other therapeutic areas can accelerate innovation in ADHD drug delivery.
More Related Videos
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
6.5K
13:09Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
Published on: April 1, 2018
11.0K
Related Concept Videos
01:30Attention-Deficit/Hyperactivity Disorder
1.1K
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
1.1K
01:26Oral Drug Delivery Systems: Continuous-Release Systems
74
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
74
01:22Drug Delivery: Miscellaneous Routes
885
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
885
01:28Drug Therapy
325
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
325
01:16Drug Delivery: Overview
999
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
999
01:23Inhaled Medications
900
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
900